On Monday, Shares of QUALCOMM, Inc. (NASDAQ:QCOM), gained 2.11% to $56.23.
QUALCOMM, declared its intention to invest up to $150 million in Indian startup companies across all stages as part of its commitment to India during a meeting with Prime Minister Narendra Modi at the Digital Economy event in San Jose. Qualcomm Ventures will advise and direct Qualcomm’s activities with respect to these planned investments.
Qualcomm has been investing in promising Indian startups since 2007 and there are more than 20 Indian companies as part of its global portfolio. Sectors of investment vary across the mobile ecosystem and comprise hardware, software platforms, e-commerce, healthcare, location based services and retail technology. Initiatives such as the QPrize™ competition, a global seed investment competition, in addition to an early stage fund, are part of the team’s efforts in encouraging early stage entrepreneurs.
Qualcomm directly invests in Indian mobile and internet start-up companies to keenly foster the local ecosystem. Portfolio companies comprise Yourstory, a media tech platform for entrepreneurs; Portea Medical, an in-home healthcare provider; and MapMyIndia, a provider of digital map, navigation, and tracking products and services. Indian companies receiving funding can benefit from Qualcomm’s insights on mobile technologies and utilize Qualcomm’s relationships throughout the industry. Qualcomm Ventures’ India team also provides unique support through its comprehensive knowledge and understanding of the region.
QUALCOMM Incorporated (Qualcomm) designs, manufactures and market digital communications products and services based on Code Division Multiple Access (CDMA), Orthogonal Frequency Division Multiple Access (OFDMA) and other technologies.
Shares of JetBlue Airways Corporation (NASDAQ:JBLU), inclined 1.03% to $26.49, during its last trading session.
JetBlue Airways Corporation, declared service to Nashville International Airport (BNA) will start May 5, 2016. The airline will operate two daily non-stop roundtrips between Nashville and Boston Logan International Airport (BOS) and one daily roundtrip between Nashville and Fort Lauderdale-Hollywood International Airport (FLL).
To celebrate the declared start date of service JetBlue is offering introductory fares starting at $59 one way (a) for flights between Nashville and Boston and introductory fares starting at $79 one way (a) for flights between Nashville and Fort Lauderdale-Hollywood. Seats are on sale starting recently and may be purchased at JetBlue.com.
JetBlue Airways Corporation is a passenger carrier company. The Company provides air transportation services across the United States, Caribbean and Latin America. The Company operates Airbus A321, Airbus A320 and EMBRAER 190 aircraft types.
Shares of Energen Corporation (NYSE:EGN), inclined 3.26% to $55.41, during its last trading session.
Energen Corporation, has been given a consensus rating of “Buy” by the seventeen research firms that are presently covering the stock, Analyst Ratings.Net reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $75.13.
Energen Corporation (Energen) is an oil and gas exploration and production company with headquarters in Birmingham, Alabama. The Company has 1.1 billion barrels of oil-equivalent proved, probable, and possible reserves and another 2.2 billion barrels of oil-equivalent contingent resources.
Finally, Esperion Therapeutics Inc (NASDAQ:ESPR), ended its last trade with -6.83% loss, and closed at $24.97.
Esperion Therapeutics, a pharmaceutical company focused on developing and commercializing a first-in-class, oral therapy for low-density lipoprotein cholesterol (LDL-C) lowering for the treatment of patients with hypercholesterolemia, offered an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the U.S. Food and Drug Administration (FDA).
Esperion plans to conduct multiple Phase 3 clinical trials that will separately evaluate patients with statin intolerance, in addition to patients who are inadequately treated despite maximally tolerated statin therapy. This dual strategy will leverage the profile of ETC-1002 to differentiate the drug in the statin intolerant patient population, while also preserving the opportunity to develop the drug as an add-on to maximally tolerated statin therapy.
For statin intolerant patients who have a high unmet medical need, Esperion is working with key opinion leaders and will continue to seek advice from global regulatory authorities on the design of the Phase 3 program. Specifics of the Phase 3 development program are anticipated to be finalized by the first half of 2016.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
